198 related articles for article (PubMed ID: 38429428)
1. EGFR signaling and pharmacology in oncology revealed with innovative BRET-based biosensors.
Gross F; Mancini A; Breton B; Kobayashi H; Pereira PHS; Le Gouill C; Bouvier M; Schann S; Leroy X; Sabbagh L
Commun Biol; 2024 Mar; 7(1):250. PubMed ID: 38429428
[TBL] [Abstract][Full Text] [Related]
2. Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.
Tan PK; Wang J; Littler PL; Wong KK; Sweetnam TA; Keefe W; Nash NR; Reding EC; Piu F; Brann MR; Schiffer HH
Mol Pharmacol; 2007 Dec; 72(6):1440-6. PubMed ID: 17715395
[TBL] [Abstract][Full Text] [Related]
3. Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.
Zhu VW; Klempner SJ; Ou SI
Trends Cancer; 2019 Nov; 5(11):677-692. PubMed ID: 31735287
[TBL] [Abstract][Full Text] [Related]
4. Marked synergy by vertical inhibition of EGFR signaling in NSCLC spheroids shows SOS1 is a therapeutic target in EGFR-mutated cancer.
Theard PL; Sheffels E; Sealover NE; Linke AJ; Pratico DJ; Kortum RL
Elife; 2020 Sep; 9():. PubMed ID: 32897190
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
6. Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify
Talwelkar SS; Nagaraj AS; Devlin JR; Hemmes A; Potdar S; Kiss EA; Saharinen P; Salmenkivi K; Mäyränpää MI; Wennerberg K; Verschuren EW
Mol Cancer Ther; 2019 Oct; 18(10):1863-1874. PubMed ID: 31320402
[TBL] [Abstract][Full Text] [Related]
7. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
[TBL] [Abstract][Full Text] [Related]
8. Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression.
Tanaka H; Sakagami H; Kaneko N; Konagai S; Yamamoto H; Matsuya T; Yuri M; Yamanaka Y; Mori M; Takeuchi M; Koshio H; Hirano M; Kuromitsu S
Mol Cancer Ther; 2019 Aug; 18(8):1366-1373. PubMed ID: 31092564
[TBL] [Abstract][Full Text] [Related]
9. pYtags enable spatiotemporal measurements of receptor tyrosine kinase signaling in living cells.
Farahani PE; Yang X; Mesev EV; Fomby KA; Brumbaugh-Reed EH; Bashor CJ; Nelson CM; Toettcher JE
Elife; 2023 May; 12():. PubMed ID: 37212240
[TBL] [Abstract][Full Text] [Related]
10. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
[TBL] [Abstract][Full Text] [Related]
11. Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer.
Niederst MJ; Engelman JA
Sci Signal; 2013 Sep; 6(294):re6. PubMed ID: 24065147
[TBL] [Abstract][Full Text] [Related]
12. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
[TBL] [Abstract][Full Text] [Related]
13. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
[TBL] [Abstract][Full Text] [Related]
14. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
[TBL] [Abstract][Full Text] [Related]
15. Conserved roles for receptor tyrosine kinase extracellular regions in regulating receptor and pathway activity.
Gonzalez-Magaldi M; McCabe JM; Cartwright HN; Sun N; Leahy DJ
Biochem J; 2020 Nov; 477(21):4207-4220. PubMed ID: 33043983
[TBL] [Abstract][Full Text] [Related]
16. microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers.
Gasparini P; Cascione L; Landi L; Carasi S; Lovat F; Tibaldi C; Alì G; D'Incecco A; Minuti G; Chella A; Fontanini G; Fassan M; Cappuzzo F; Croce CM
Proc Natl Acad Sci U S A; 2015 Dec; 112(48):14924-9. PubMed ID: 26627242
[TBL] [Abstract][Full Text] [Related]
17. Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.
Ayoub MA; See HB; Seeber RM; Armstrong SP; Pfleger KD
PLoS One; 2013; 8(5):e64672. PubMed ID: 23700486
[TBL] [Abstract][Full Text] [Related]
18. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
[TBL] [Abstract][Full Text] [Related]
19. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
20. AXL and acquired resistance to EGFR inhibitors.
Postel-Vinay S; Ashworth A
Nat Genet; 2012 Jul; 44(8):835-6. PubMed ID: 22836088
[No Abstract] [Full Text] [Related]
[Next] [New Search]
